Home / Health / Breakthrough: Finerenone Offers New Path for Premature Ovarian Insufficiency
Breakthrough: Finerenone Offers New Path for Premature Ovarian Insufficiency
10 Feb
Summary
- An oral medicine for kidney and heart disease shows promise for ovarian insufficiency.
- Finerenone curbs fibrosis, facilitating follicle growth in experiments.
- This discovery may lead to a new, less invasive infertility therapy.
A novel approach to treating premature ovarian insufficiency has emerged from research conducted by Japanese and international scientists. They found that finerenone, an oral medication currently prescribed for chronic kidney disease and heart failure, demonstrates significant efficacy in addressing this condition.
Premature ovarian insufficiency affects women before the age of 40, leading to the cessation of menstrual cycles and ovarian fibrosis, which impedes follicle development. Finerenone has been observed to effectively curb fibrosis in both kidney and heart tissues.
Experiments on mice confirmed finerenone's ability to promote follicle growth, resulting in increased offspring production without abnormalities. This led to a clinical trial where finerenone was administered to patients alongside ovary stimulation and ovum maturation medicines, culminating in the successful retrieval of a fertilized egg through in vitro fertilization.
The research team, including experts from Juntendo University and the University of Hong Kong, published their findings in the U.S. journal Science. They aim to further optimize ovary stimulation and identify even more effective treatments, potentially offering a less burdensome infertility therapy compared to existing methods like in vitro activation.
